BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 1337163)

  • 1. Low-calcium dialysis fluid and oral calcium carbonate in CAPD. A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia.
    Hutchison AJ; Freemont AJ; Boulton HF; Gokal R
    Nephrol Dial Transplant; 1992; 7(12):1219-25. PubMed ID: 1337163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
    Weinreich T; Ritz E; Passlick-Deetjen J
    Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. The Peritoneal Dialysis Multicenter Study Group.
    Weinreich T; Passlick-Deetjen J; Ritz E
    Am J Kidney Dis; 1995 Mar; 25(3):452-60. PubMed ID: 7872324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypercalcaemia, hypermagnesaemia, hyperphosphataemia and hyperaluminaemia in CAPD: improvement in serum biochemistry by reduction in dialysate calcium and magnesium concentrations.
    Hutchison AJ; Were AJ; Boulton HF; Mawer EB; Laing I; Gokal R
    Nephron; 1996; 72(1):52-8. PubMed ID: 8903861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful control of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis using magnesium carbonate and calcium carbonate as phosphate binders.
    Parsons V; Baldwin D; Moniz C; Marsden J; Ball E; Rifkin I
    Nephron; 1993; 63(4):379-83. PubMed ID: 8459870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients.
    Johnson DW; Rigby RJ; McIntyre HD; Brown A; Freeman J
    Nephrol Dial Transplant; 1996 Jan; 11(1):88-93. PubMed ID: 8649658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia.
    Ittel TH; Schäfer C; Schmitt H; Gladziwa U; Sieberth HG
    Klin Wochenschr; 1991 Jan; 69(2):59-67. PubMed ID: 2027271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
    Bro S; Brandi L; Olgaard K
    Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low- and high-turnover bone disease in continuous ambulatory peritoneal dialysis: effects of low-Ca2+ peritoneal dialysis solution.
    Carozzi S; Nasini MG; Santoni O; Pietrucci A
    Perit Dial Int; 1993; 13 Suppl 2():S473-5. PubMed ID: 8399644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The requirement of low calcium dialysate in patients on continuous ambulatory peritoneal dialysis receiving calcium carbonate as a phosphate binder.
    Cheng IK; Lu HB; Chan CY; Cheng SW; Robinson JD; Tam SC; Lo WK; Cheung WC
    Clin Nephrol; 1993 Aug; 40(2):100-5. PubMed ID: 8222365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low calcium dialysate and hyperparathyroidism.
    Duncan R; Cochrane T; Bhalla C; Michael J; Richards NT; Adu D
    Perit Dial Int; 1996; 16 Suppl 1():S499-502. PubMed ID: 8728256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAPD with low calcium dialysate and calcium carbonate: results of a 24-week study.
    Honkanen E; Kala AR; Grönhagen-Riska C; Ikäheimo R
    Adv Perit Dial; 1992; 8():356-61. PubMed ID: 1361822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminium avoidance in haemodialysis patients.
    Sawyer N; Noonan K; Altmann P; Marsh F; Cunningham J
    Nephrol Dial Transplant; 1989; 4(2):105-9. PubMed ID: 2496350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of calcium carbonate to treat the hyperphosphataemia of chronic renal failure.
    Williams B; Vennegoor M; O'Nunan T; Walls J
    Nephrol Dial Transplant; 1989; 4(8):725-9. PubMed ID: 2510082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low calcium (1.25 mmol/L) dialysate can normalize relative hypoparathyroidism in CAPD patients with low bone turnover.
    Shigematsu T; Kawaguchi Y; Kubo H; Nakayama M; Kato N; Yamamoto H; Osaka N; Hayakawa H; Ogawa A; Sakai O
    Adv Perit Dial; 1996; 12():250-6. PubMed ID: 8865914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low calcium peritoneal dialysis solution. Effects on calcium metabolism and bone disease in CAPD patients.
    Carozzi S; Nasini MG; Schelotto C; Caviglia PM; Santoni O; Pietrucci A
    ASAIO J; 1992; 38(3):M593-5. PubMed ID: 1457929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Audit of the use of calcium carbonate as a phosphate binder in 100 patients treated with continuous ambulatory peritoneal dialysis.
    Davenport A; Goel S; MacKenzie JC
    Nephrol Dial Transplant; 1992; 7(7):632-5. PubMed ID: 1323075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal osteodystrophy in CAPD.
    Hutchison AJ; Freemont AJ; Lumb GA; Gokal R
    Adv Perit Dial; 1991; 7():237-9. PubMed ID: 1680434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.